

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)



127th MAINE LEGISLATURE

SECOND REGULAR SESSION-2016

Legislative Document

No. 1552

H.P. 1057

House of Representatives, January 12, 2016

An Act To Reduce Morbidity and Mortality Related to Injected Drugs

(AFTER DEADLINE)

Approved for introduction by a majority of the Legislative Council pursuant to Joint Rule 205.

Reference to the Committee on Health and Human Services suggested and ordered printed.

A handwritten signature in cursive script that reads "R B. Hunt".

ROBERT B. HUNT
Clerk

Presented by Representative VACHON of Scarborough.
Cosponsored by Senator HASKELL of Cumberland and
Representatives: DUNPHY of Embden, GATTINE of Westbrook, HEAD of Bethel,
MALABY of Hancock, REED of Carmel, SANBORN of Gorham, TURNER of Burlington,
WARD of Dedham.

1 **Be it enacted by the People of the State of Maine as follows:**

2 **Sec. 1. 22 MRSA §1341, sub-§4** is enacted to read:

3 **4. Funding.** This subsection governs funding for hypodermic apparatus exchange
4 programs certified pursuant to this section.

5 A. The Maine Center for Disease Control and Prevention shall allocate any funds
6 appropriated for hypodermic apparatus exchange programs among programs based on
7 rates of intravenous drug use and negative health outcomes related to drug use in the
8 geographic area surrounding a program and the amount of services historically
9 provided by the program, except that the center may award funds through a
10 competitive grant process in order to facilitate the operation of programs in counties
11 without programs.

12 B. Unless the use of funds to support a hypodermic apparatus exchange program is
13 prohibited by the original funding source, the department may not prohibit funds it
14 awards to an entity involved in HIV, viral hepatitis and substance abuse issues from
15 being used to support a hypodermic apparatus exchange program as long as the
16 services the program provides can reasonably be expected to contribute to the desired
17 result identified when the funding is first made available.

18 **Sec. 2. Appropriations and allocations.** The following appropriations and
19 allocations are made.

20 **HEALTH AND HUMAN SERVICES, DEPARTMENT OF (FORMERLY DHS)**

21 **Maine Center for Disease Control and Prevention 0143**

22 Initiative: Appropriates funds for existing hypodermic apparatus exchange programs
23 certified by the Maine Center for Disease Control and Prevention.

24			
25	GENERAL FUND	2015-16	2016-17
26	All Other	\$0	\$50,000
27			
28	GENERAL FUND TOTAL	<u>\$0</u>	<u>\$50,000</u>

29 **Maine Center for Disease Control and Prevention 0143**

30 Initiative: Appropriates funds to facilitate the growth of new hypodermic apparatus
31 exchange programs certified by the Maine Center for Disease Control and Prevention in
32 counties without a program.

33			
34	GENERAL FUND	2015-16	2016-17
35	All Other	\$0	\$25,000
36			
37	GENERAL FUND TOTAL	<u>\$0</u>	<u>\$25,000</u>

38

1	HEALTH AND HUMAN SERVICES,	2015-16	2016-17
2	DEPARTMENT OF (FORMERLY DHS)		
3	DEPARTMENT TOTALS		
4			
5	GENERAL FUND	\$0	\$75,000
6			
7	DEPARTMENT TOTAL - ALL FUNDS	\$0	\$75,000

8 **SUMMARY**

9 This bill provides funding for existing and new hypodermic apparatus exchange
10 programs certified by the Department of Health and Human Services, Maine Center for
11 Disease Control and Prevention. The center must allocate funds appropriated for existing
12 hypodermic apparatus exchange programs among programs based on rates of intravenous
13 drug use and negative health outcomes related to drug use in the geographic area
14 surrounding a program and the amount of services historically provided by the program,
15 except that funds awarded in order to facilitate the operation of programs in counties
16 without a program may be awarded through a competitive grant process. It also provides
17 that, unless the use of funds to support a hypodermic apparatus exchange program is
18 prohibited by the original funding source, the department may not prohibit funds it
19 awards to an entity involved in HIV, viral hepatitis and substance abuse issues from being
20 used to support a hypodermic apparatus exchange program as long as the services the
21 program provides can reasonably be expected to contribute to the desired result identified
22 when the funding is first made available.